News

Certain transitional activities will be continued at the facility for the next few weeks to ensure proper and compliant closure of the facility, however as of January 31,

The collaboration between Novartis and Gen-Probe was established in 1998. It was previously scheduled to expire in 2013. Under the original terms of the agreement, the companies shared

Upon investigational new drug and investigational medicinal product dossier clearance by the regulatory authorities, Pluristem plans to initiate clinical trials in Europe and in the US, administering PLX-PAD

These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample preparation platform and their next generation sample to answer clinical molecular

Mr Conterno will succeed Deirdre Connelly, who has led Lilly’s US operations since 2005. Ms Connelly has resigned from the company to pursue other opportunities. Mr Conterno will

Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. Warner Chilcott has previously announced the filing of

Zoll Medical is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation technologies, ventilation, and fluid resuscitation, Zoll provides a

Novartis said that Coartem dispersible contains the same amounts of artemether and lumefantrine as Coartem, the leading artemisinin-based combination therapy (ACT) in Africa, and is the first dispersible

The trial is a proof-of-concept, open-label study with pediatric subjects randomized according to weight group and titrated to receive one of four doses over a six-week treatment period.